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Abstract
Most of humanity is chronically infected with human herpesvirus 6 (HHV-6), with viral repli-
cation controlled at least in part by a poorly characterized CD4 T cell response. Identification
of viral epitopes recognized by CD4 T cells is complicated by the large size of the herpesvi-
rus genome and a low frequency of circulating T cells responding to the virus. Here, we
present an alternative to classical epitope mapping approaches used to identify major tar-
gets of the T cell response to a complex pathogen like HHV-6B. In the approach presented
here, extracellular virus preparations or virus-infected cells are fractionated by SDS-PAGE,
and eluted fractions are used as source of antigens to study cytokine responses in direct ex
vivo T cell activation studies. Fractions inducing significant cytokine responses are ana-
lyzed by mass spectrometry to identify viral proteins, and a subset of peptides from these
proteins corresponding to predicted HLA-DR binders is tested for IFN-γ production in sero-
positive donors with diverse HLA haplotypes. Ten HHV-6B viral proteins were identified as
immunodominant antigens. The epitope-specific response to HHV-6B virus was complex
and variable between individuals. We identified 107 peptides, each recognized by at least
one donor, with each donor having a distinctive footprint. Fourteen peptides showed
responses in the majority of donors. Responses to these epitopes were validated using in
vitro expanded cells and naturally expressed viral proteins. Predicted peptide binding affini-
ties for the eight HLA-DRB1 alleles investigated here correlated only modestly with the
observed CD4 T cell responses. Overall, the response to the virus was dominated by pep-
tides from the major capsid protein U57 and major antigenic protein U11, but responses to
other proteins including glycoprotein H (U48) and tegument proteins U54 and U14 also
were observed. These results provide a means to follow and potentially modulate the CD4
T-cell immune response to HHV-6B.
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Introduction
HHV-6B is a herpesvirus widely spread in human populations. In western countries most indi-
viduals get infected with HHV-6B before their second year of life [1] and suffer a relative mild
febrile syndrome that recedes spontaneously, and is followed in some cases by a rash referred
to as roseola, exanthema subitum, or sixth disease [2]. Although most children recover from
HHV-6B infection without sequelae, primary infection is a major cause of hospital visits in
young children [3]. HHV-6B establishes a lifelong persistent infection that later in life is associ-
ated with drug-induced hypersensitivity syndrome with eosinophilia and systemic symptoms
(DRESS) [4] and in transplant recipients with graft-versus-host disease (GVHD) [5,6], enceph-
alitis [7–9], and delayed engraftment, among others complications [10]. HHV-6B shares 90%
nucleotide sequence identity with HHV-6A [11], but primary infection with this later virus
does not seem to produce a clinical disease; later in life, HHV-6A reactivation has been associ-
ated with multiple sclerosis (MS) [12].
Adaptive immune responses to herpesviruses are critical in the control of virus replication,
as shown by high load of virus in immunosuppressed individuals [13]. Anti-viral drugs, which
are not devoid of adverse reactions [14], are used to control viral replication. Immunotherapies
have been developed for the human herpesviruses cytomegalovirus (HCMV) and Epstein-Barr
virus (EBV) [15]. Similar approaches for HHV-6 are limited by the lack of well-characterized
HHV-6 antigens. Recently, some success was achieved in controlling viral reactivation after
hematopoietic stem cell therapy using in vitro expanded T cells targeting antigens from adeno-
virus, BK virus, HCMV, EBV, and HHV-6 [16].
CD4 T cell responses have been shown to be a major determinant in the control of herpesvi-
rus infections in animal models and in humans. In experimentally infected rhesus macaques
with simian varicella virus, a model for pediatric varicella zoster virus (VZV), CD4 T cells are
more important to control virus than either antibodies or CD8 T cells [17]. Patients with CD4
T cell deficiencies have an increased susceptibility to herpesvirus infections [18]. Transplant
patients vaccinated with inactivated varicella vaccine prior to hematopoietic stem cell trans-
plantation have a lower risk of zoster, and protection correlates with the CD4 T cell response to
VZV [19]. In immunosuppressed patients, low CD4 T cell counts are correlated with EBV-
related diseases [20]; in renal transplant patients, CD4 T cells are critical for recovery of
HCMV infection [21] and in HIV patients low numbers of CD4 T cells are correlated with
HCMV-associated diseases [22]. In children with primary HCMV infection, virus shedding in
urine (a measure of viral load) correlated with delayed CD4 T cell responses [23]. Based on
these studies on other herpesviruses, efforts to develop immunotherapy for HHV-6 might ben-
efit from identification of CD4 T cell epitopes.
T cell responses to HHV-6 have been studied mostly in healthy adults [24]. These studies
indicate a low frequency of HHV-6-antigen specific T cells in peripheral blood. Challenge of
peripheral blood mononuclear cells (PBMCs) with HHV-6 antigens results in the expansion of
CD4 T cells that secrete high levels of IFN-γ with Th2-associated cytokines IL-4 and IL-10 also
prominent in the CD4 T cell response [25]. A large fraction of these cells have a cytolytic capac-
ity [25–27]. CD8 T cell responses can be shown in ex vivo assays, but only few investigators
have been able to established lines or clones [27–30].
A gap in the current understanding of the T cell response to HHV-6 is the definition of
immunodominant T cell antigens. The large number of predicted open reading frames (~100)
in HHV-6 makes traditional approaches costly and labor intensive. For these reasons, studies
to date have limited the number of potential candidates to study. Nastke et al [25] and Martin
et al [28] have used computer-based epitope predictions to identify potential epitopes for
screening. Gerdemann et al [27], Iampietro et al [29], and Halawi et al [30] used overlapping
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peptides covering the entire sequence of HHV-6 proteins which are homologues of HCMV
immunodominant antigens. Tejada-Simon et al [31] used an even more selective approach,
screening for T cell responses from the HHV-6 protein U24 using peptides that share signifi-
cant homology with self-proteins. Overall, only 16 CD8 epitopes and 14 CD4 T cell epitopes
from HHV-6 have been identified (Reviewed in [32]).
In this report, a more comprehensive approach was developed, which combines screening
of T cell responses to naturally-produced HHV-6B virus proteins fractionated by gel electro-
phoresis, mass-spectrometry identification of viral proteins present in positive fractions, and
ex vivo testing of peptide pools from these proteins selected based on predicted MHC binding
affinity. Using this approach, over 100 new CD4 T cell epitopes from HHV-6B were identified.
Robust CD4 T cell responses to a few abundant HHV-6B proteins were observed in all donors,
but within these proteins the responses to specific epitopes were quite variable between donors.
Fourteen peptides that were recognized by the majority of the donors tested were validated.
These peptides might be useful to track and possibly modulate HHV-6B responses in a diverse
population.
Materials and Methods
Virus
HHV-6B, strain Z29 was kindly provided by S. Jacobson (NINDS, Bethesda, MD, USA). The
virus was propagated in SupT1 cells (ATCC # CRL-1942) that were maintained in RPMI 1640
medium (Cellgro, Mediatech Inc., Manassas, VA) supplemented with L-glutamine (2 mM),
penicillin (100 U/ml), streptomycin (100 μg/ml) (all from Gibco-Life Technologies, Grand
Island, NY) and 10% heat inactivated fetal bovine serum (FBS, HyClone™, GE Healthcare,
Pittsburg, PA). Cells were infected by co-culture of non-infected SupT1 and HHV-6B
Z29-infected SupT1 at a ratio 5:1. Infected cultures were maintained at a density of 1 x 106
cells/ml in medium supplemented with 5% FBS, and the infection was monitored by measuring
the average diameter of the cells and cell viability using a cell counter (Nexcelom Biosciences,
Lawrence, MA).
Antigen preparation
Supernatant from infected cell-cultures was collected when cytopathic effect was evident (i.e.,
average size of cells was greater than 14.4 μm). Collected supernatant was cleared by sequential
centrifugation at 290 x g for 10 min and at 2,000 x g for 20 min. A crude virus pellet was
obtained by centrifugation of the supernatant at 39,000 x g for 75 min. The virus pellet was
resuspended in 10 mM Tris-HCl pH 7.5 / 150 mMNaCl / 5 mM EDTA (buffer TNE). Infected
or non-infected SupT1 cells also were collected. Cells were lysed by repeated freeze/thaw cycles,
spun at 1,500 x g for 10 min and the supernatant was collected (cell lysate). HHV-6B crude
virus pellet and cell lysates from non-infected and HHV-6B-infected cells were heat-inactivated
(at 56°C in a water bath for 1 hour) and used as source of antigens for T cell stimulation.
Peripheral blood mononuclear cells (PBMCs) and antigen-expanded T
cell populations
Blood from healthy donors was collected under a protocol approved by the Medical School
Institutional Review Board of the University of Massachusetts (IRB protocol #1668). All sub-
jects provided written informed consent for participation in the study. Donors HLA DRB1
haplotype was determined by the UMass MHC Haplotyping Core Facility. PBMCs were iso-
lated from blood from seropositive donors (Table 1) using Ficoll-Paque (GE Healthcare,
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Pittsburg, PA) and used immediately in T cell assays. Alternatively, HHV-6B or peptide-
expanded oligoclonal T cell lines were generated by a single in vitro expansion with fresh
PBMCs, using 5 μg/ml of viral antigens (heat-inactivated HHV-6B cell lysate or crude virus
pellet) or 10 μg/ml peptides, in complete RPMI (RPMI 1640 supplemented with 10% AB+
human serum (Interstate Blood Bank, Inc., Memphis, TN), 50 μM beta-mercaptoethanol,
1 mM non-essential amino acids, 1 mM sodium pyruvate, 100 U/ml penicillin and 100 mg/ml
streptomycin (all Gibco-Life Technologies, Grand Island, NY). After 3 days, IL-2 (100 U/ml;
Chiron, Emoryville, CA) was added to the medium and cells were maintained for 15–21 days
and used in T cell assays. A T cell clone recognizing 6BZ_1084 was obtained from peptide-spe-
cific oligoclonal T cell populations by limiting dilution. EBV-transformed B cells were pro-
duced by infection of PBMCs with EBV as previously reported [33].
Depletion of cell populations
Heparinized whole blood was depleted from CD4, CD8 or CD19 with RosetteSep™Human
Depletion Cocktails following manufacturer’s protocols (StemCell Technologies, Vancouver,
Canada).
HHV-6B and HCMV serologic status
HHV-6B IgG titer was determined in serum using HHV-6 IgG Antibody IFA Kit (Advanced
Biotechnologies Inc., Columbia, MD) and HCMV IgG was measured in serum using CMV IgG
Enzyme Immunoassay Test Kit (MP Biomedicals, Solon, OH), following manufacturer’s
instructions.
Fractionation of viral antigens
Ten to fifteen micrograms of total protein were loaded in 7.5% SDS-PAGE gel (BioRad Labora-
tories Inc., Hercules, CA) in duplicate lanes. One lane of the gel was used for coomassie blue
staining. A second lane was excised, washed in distilled water for 10 minutes, rinsed, and sliced
into ten fractions from top to bottom. Half of each fraction was mashed in a microcentrifuge
tube using a pestle micro-homogenizer (Kontes/Kimble Chase, Vineland NJ), and resuspended
in 0.5 ml complete RPMI for use in gel band T cell assays. The other half of each fraction was
minced with a razor blade and used for protein identification using liquid chromatography and
tandem mass spectrometry.
Table 1. DRB1 haplotype and serologic status of donors used in this study.
Donor Id DRB1* HHV-6 IgG1 HCMV IgG2
037 07:01/07:01 1:1280 -
118 04:04/14:01 1:640 -
130 11:01/13:02 1:320 +
132 13:02/16:01 1:160 -
131 01:01/04:07 1:80 +
1. HHV-6 IgG titer measured by IFA
2. HCMV IgG status measured by ELISA
doi:10.1371/journal.pone.0142871.t001
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Gel band T cell stimulation assay
Freshly isolated PBMCs (1x106) were mixed with the gel fraction suspension, and supernatants
were assayed for levels of IFN-γ by ELISA (BD OptEIA, BD Biosciences, San Diego, CA) after
120 hours. Alternatively, in vitro-expanded cells (1x105) were incubated with autologous γ-
irradiated PBMCs (2x105) and mixed with the gel fraction suspension, and supernatants
assayed after 48 hours.
Liquid chromatography and tandemmass spectrometry (LC-MS/MS)
In-gel digestion protocol and LC-MSE was used to identify proteins in gel fractions. Proteins in
the gel pieces were reduced with dithiotreitol, alkylated with iodoacetamide and digested with
porcine trypsin (Princeton Separations Inc., Freehold, NJ) (100 ng / mg protein), at 30°C over-
night. Peptides were extracted by successive washes with dimethylformamide and 50% acetoni-
trile / 5% formic acid, dried and resuspended in 5% acetonitrile / 0.1% formic acid. The peptide
mix was analyzed using a UPLC–Q-ToF Premier System (Waters Corporation, Milford, MA)
operated in MSE acquisition mode. Raw data were processed using ProteinLynx Global Server
(PLGS) software v2.3 (Waters Corporation) to generate the precursor and product ions mass
list. Each processed file was searched against a database containing HHV-6B Z29, bovine and
human proteins sequences (NCBI, download 2009) using the IdentityE search algorithm within
PLGS.
Epitope prediction
To predict HLA-DR1 (DRB101:01) epitopes we used the HHV-6B Z29 sequence
(GI:5733510) from the NCBI database. Each potential 9-mer binding frame was scored using a
consensus binding prediction algorithm combining TEPITOPE (P9) [34] and SYFPEITHI [35]
scores [36]. Predicted epitopes with scores> -1.0 (P9) and> 18 (SYFPEITHI) were selected
for synthesis of peptides in which the 9-mer sequences were extended by the preceding and fol-
lowing four amino acids in the protein sequence. Cysteine residues in the peptides were substi-
tuted by serine (in which case, names of peptides were appended with “s”). The NetMHCIIPan
3.0 server [37] (http://www.cbs.dtu.dk/services/NetMHCIIpan/) was used to predict HLA-DR
binding affinities (IC50 and percentile rank), using the “peptide” mode which reports value for
the highest-score binding register in each peptide. For comparison with T cell epitope data in
each donor, the HLA-DR allele with higher predicted binding affinity to each peptide was used.
Epitope screening and validation
IFN-γ ELISpot (eBiosciences, San Diego, CA) assay was performed for the analysis of T cell
responses to peptides pools and to individual peptides. Peptides were obtained from Sigma
PepScreen (The Woodlands, TX) or 21st Century Biochemical (Marlborough, MA). For screen-
ing, freshly isolated PBMCs (3-4x105) were incubated with antigen for 48 hours. For validation,
in vitro-expanded cells (2-5x104) plus autologous γ-irradiated PBMCs (5-10x104) were incu-
bated with antigen for 24 hours. Antigen sources included pools of 7–12 peptides (5 μg/ml
each), individual peptides, (5 μg/ml), or controls. Positive controls included crude virus pellet
purified from culture supernatant, lysate of HHV-6B-infected cells, or a commercial HCMV
lysate (Advanced Biotechnologies Inc., Columbia, MD). Negative controls included complete
RPMI + DMSO and lysate of uninfected cells. Two wells for each tested pool or peptide, 2–4
wells for positive controls and 4–6 wells for negative controls were usually tested. Secreted
IFN-γ was detected following manufacturer’s protocol. Plates were analyzed using the
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Immunospot Image Analyzer and ImmunoSpot 3.2 software. Heat-maps were obtained using
Gene-E (http://www.broadinstitute.org/cancer/software/GENE-E/index.html).
Statistical analysis of ELISpot data
Positive responses were identified based on a distribution-free resampling approach and an
empirical rule. The distribution-free resampling (DFR2x) algorithm described by Moodie et al
[38] is available online at [http://www.scharp.org/zoe/runDFR/]. This method was designed to
address the specific characteristics of the ELISpot setup. It is based in repeated permutation of
samples and controls. If the null hypothesis (H0) is true, the permutation of the data between
the antigen and the control should not affect the statistics. H0 in DFR2x method is defined as:
“the mean of experimental wells is less than or equal than twice the mean of the control wells”.
The permutation or bootstrap test is combined with a method that introduces adjustment for
multiple comparisons (Westfall-Young method). DFR2x is very sensitive to detect intermediate
to high positive responses while maintaining a low false positive rate. The method requires at
least 4 wells for control and duplicate wells for the experimental samples. The empirical rule
(ER) uses the raw data from each plate and donor (spots-forming units (SFU) per well); posi-
tive responses were defined as responses higher than the mean of the negative control plus 3
times the standard deviation of the negative control. Next, the variability was assessed by con-
sidering the dispersion index (equal to the variance divided by the mean) for each plate and
donor; values with dispersion index beyond the 95th percentile were rejected. Finally, individual
responses below 6 spots/well were excluded.
Peptide binding assay
A fluorescence polarization (FP) assay was used to measure the relative binding affinity of pep-
tides to purified HLA-DR1 (HLA-DRA01:01; DRB101:01) as described [39]. Briefly, 100 nM
soluble recombinant HLA-DR1 was incubated with 25 nM influenza hemagglutinin HA306-318
peptide (acetyl-PRFVKQNTLRLAT) labeled with Alexa488 tetrafluorophenyl ester (Invitro-
gen, Eugene, OR), together with unlabeled test peptides, included as five-fold dilution series
starting from 100 μM. Competition of each test peptide with probe Alexa488-HA306-318 for
binding to HLA-DR1 was measured by FP (Victor X Multilabel Plate Reader, PerkinElmer,
Waltham, MA) after incubation at 37°C for 72 hours. The percent bound at each concentration
of test peptide was determined using known values for free (70 mP) and bound (280 mP) Alex-
a488-HA306-318, and the data was fit to a competition binding equation y = 1/(1+[pep]/IC50),
where [pep] is the concentration of test peptide, y is the percent probe peptide bound at that
concentration, and IC50 is the concentration of test peptide required for 50% inhibition of
probe peptide binding.
Results
IFN-γ responses of freshly isolated PBMCs to HHV-6B
Wemonitored IFN-γ, a cytokine prominently produced in response to HHV-6 [25,40], in cul-
ture supernatants of PBMCs from healthy seropositive donors (Table 1) challenged with two
sources of HHV-6B antigens: extracellular virus pelleted from culture supernatant of infected
cells and lysate from virus-infected cells. Both sources were heat-inactivated, and relevant neg-
ative controls were used. IFN-γ secretion in response to stimulation with both sources of anti-
gens was observed for every donor, while low or non-detectable levels in responses to the
negative controls (Fig 1A). The frequency of IFN-γ-producing cells measured using ELISpot
assay and reported as SFU per million cells, is shown in Fig 1B for the same set of antigens and
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controls as in Fig 1A. Low or non-detectable responses were observed with negative controls,
while increased responses were detected in the presence of viral antigens, with stronger
responses to the extracellular virus. The frequency of IFN-γ-producing cells induced by viral
antigens was low, with an average of 300 SFU/106 PBMCs or 0.03 ± 0.01% (n = 5) induced by
extracellular virus, and an average of 100 SFU/106 PBMCs or 0.01± 0.01% (n = 5), induced by
the infected-cell lysate. We used a depletion approach to study the role of different cell subpop-
ulations in the regulation of IFN-γ production. Depletion of CD4 T cells significantly reduced
the levels of IFN-γ as compared to levels obtained with whole PBMCs (about 70% reduction)
(Fig 1C), suggesting that CD4 T cells have a major role in the regulation of IFN-γ production
by PBMCs. Depletion of other lymphocyte subpopulations had a less marked effect. Altogether,
these results indicate that IFN-γ is produced in response to stimulation with HHV-6B viral
antigens, and that CD4 T cells are required for efficient production of this cytokine.
To identify targets of the IFN-γ response, we combined in vitro cellular immunology and
proteomics approaches (Fig 2A). HHV-6B extracellular virus pellet was fractionated using
SDS-PAGE, and proteins present in excised gel fractions were used to stimulate freshly isolated
PBMCs (Fig 2B) or cells expanded by a single round of in vitro stimulation with HHV-6B (Fig
2C). IFN-γ production in response to excised gel fractions was measured by ELISA and viral
proteins present in these fractions were identified by in-gel trypsin digestion and LC-MSE. In
PBMCs, significant IFN-γ responses to three fractions in the range MW ~100–180 kDa were
observed for both donors tested (Fig 2B, filled bars). The fraction at ~150–184 kDa induced the
strongest response in both donors. All viral peptides identified in this fraction derive from the
HHV-6B U57 protein. For the fraction at ~122–150 kDa, most of the peptides were from U11,
but peptides from U48, U14 and U57 also were identified. For the fraction at ~100–122 kDa,
peptides from U14 and U11 were identified. Four independent expanded T cell populations
derived from PBMCs from 2 donors were tested for IFN-γ production in response to
SDS-PAGE fractionated viral antigens. Six gel fractions induced strong IFN-γ responses (Fig
2C, filled bars). A total of 8 viral proteins were identified in these fractions: U57, U31, U48,
U11, U14, U100, U54 and U39. An additional experiment was performed using PBMCs, and
gel fractions from a cell lysate of HHV-6B-infected cells (data not shown). As a result, 2
Fig 1. Ex-vivo IFN-γ production by PBMCs from healthy donors in response to HHV-6B antigens (extracellular virus pellet and infected-cell lysate).
A. Total IFN-γ in cell culture supernatant measured by ELISA (fg/cell) after 120 hours incubation of PBMCs with antigens. B. Total number of IFN-γ-producing
cells measured by ELISpot (SFU/106 cells) after 48 hours incubation of PBMCs with antigens. C. Effect of depletion of CD4, CD8 or CD19 subpopulations on
IFN-γ production by total PBMCs, measured by ELISpot (presented as percentage of the response of total PBMCs). Statistical analysis: parametric paired t-
test. Each donor is represented by the same colored symbol in the different graphs.
doi:10.1371/journal.pone.0142871.g001
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Fig 2. Identification of HHV-6B targets of the IFN-γ response. A. Schematic of the experimental approach: fractionation of proteins by SDS-PAGE;
measurement of IFN-γ secretion induced by gel fractions; identification of HHV-6B proteins by proteomics in selected fractions. B and C. IFN-γ production by
PBMCs (B) or in vitro HHV-6B-expanded T cell cultures (C), in response to stimulation with gel fractions containing HHV-6B proteins. Middle panels show
SDS-PAGE profiles of extracellular virus; left panels show IFN-γ production (fg/cell) by each fraction; right panels show protein identification by proteomics
(pie charts show the numbers of tryptic peptides characterized by mass spectrometry used to identify each HHV-6B protein; numbers are shown in
parentheses). In B, individual IFN-γ responses of two different donors are shown using black (#118) and grey (#131) bars, with filled bars indicating positive
responses (values above the background mean + 3 times standard deviation). Error bars represent standard deviation of replicate measurements for each
donor. Filled-bars indicate fractions selected for proteomics analysis. In C, average IFN-γ responses of four expanded T cell cultures (from two different
donors); error bars represent the standard deviation. Filled bars indicate positive responses (values above the background mean + 3 times the standard
deviation), selected for proteomics analysis.
doi:10.1371/journal.pone.0142871.g002
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additional viral proteins were identified: U41 and U90. A summary of all proteins identified in
gel fractions that induced IFN-γ response in PBMCs and/or expanded T cell populations is pre-
sented in Table 2.
Identification of CD4 T cell epitopes in selected HHV-6B proteins
To identify CD4 T cell epitopes within the viral proteins identified by mass spectrometry
(Table 2), all potential 9-mer binding frames (core epitopes) in these proteins were evaluated
for predicted MHC binding, followed by experimental screening of the T cell responses to the
high-scoring subset of the predicted core epitopes. A previously described consensus algorithm
was used to predict binding to HLA-DR1 [34–36]. Of the 9,619 total potential 9-mer epitopes
present in 10 viral proteins, 463 epitopes predicted to be in the top fifth percentile were
selected. Peptides corresponding to these epitopes were synthesized as 17-mers, each composed
of the selected 9-mer with 4 flanking residues on each side. A summary of the predictions is
presented in Table 3 and peptide sequences, core epitopes, and predicted binding scores are
shown in S1 Table. Overall, the synthesized peptides represent 34–65% sequence coverage of
the corresponding proteins.
To facilitate screening, peptides were grouped by protein into 53 pools of 7–12 peptides per
pool (Table 3; S1 Table) according to their predicted binding score, in order to minimize the
potential for peptides within a pool to compete for MHC binding. We performed initial screen-
ing of IFN-γ responses using PBMCs from 5 normal seropositive donors by ELISpot. Fig 3A
shows representative data for three donors and pools # 1 to 29. Fig 3B shows a summary of
results from all donors and pools presented as a heat-map, with columns organized by donor
and rows by protein and then by pool number. The proteins are ranked vertically by overall T
cell response, with peptide pools within each protein ranked according to the average response.
The color scale runs from strong responses (up to 291 SFU/106 cells) shown in yellow to no
response shown in black. Overall, the magnitude of the T cell responses to the peptide pools
was relatively low, with responding T cells frequencies ranging from 0 to ~0.03% for individual
donors and peptide pools. Each pool was tested 5 times (265 tests) and overall 133 tests gave a
positive response either of two statistical tests, selected to identify relatively sparse responses
and taking into account multiple comparisons (see Methods for details). One-hundred and
nineteen tests were positive using a distribution-free resampling approach with p values less
than 0.05 considered positive (DFR2x). One hundred and twelve tests were considered positive
using the empirical rule (ER) of mean response minus background greater than three times the
Table 2. Summary of HHV-6B proteins identified by LC/MSE in gel-fractions that induced IFN-γ responses.
Protein Name ORF Accession Number MW (kDa) Antigen source1
Large tegument protein U31 Q9QJ37 240 Virus
Major capsid protein U57 Q9QJ26 152 Virus
Major DNA binding protein U41 P52538 127 Cell lysate
Immediate early protein1 U90 Q77PU6 121 Cell lysate
Major antigenic phosphoprotein pp100 U11 Q69535 96 Virus
Glycoprotein B U39 P36320 93 Virus, cell lysate
Glycoprotein H U48 P52543 80 Virus
Phosphoprotein pp85 U14 Q9QJ49 70 Virus, cell lysate
Glycoprotein Q U100 Q9QJ11 70 Virus, cell lysate
Virion transactivator U54 Q9QJ29 52 Virus, cell lysate
1. Virus: extracellular HHV-6B virus; Cell lysate: lysate of HHV-6B-infected cells
doi:10.1371/journal.pone.0142871.t002
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standard deviation of the negative control, with rejection criteria for weak and variable
responses. A summary of these results is presented in S2 Table. Fifteen pools that elicited posi-
tive responses in 4–5 donors by DFR2x were selected for further study; one additional pool
(U54-pool 21) was included given the relatively high magnitude of the response and high posi-
tive frequency by ER (5 positives out of 5 tests). Selected pools are indicated with a plus sign in
Fig 3B.
In order to identify specific epitopes, peptides in each positive pool were screened individu-
ally by IFN-γ ELISpot assay. Fig 3C shows representative data for four pools and Fig 3D shows
heat-maps summarizing the IFN-γ responses for individual peptides in the 16 pools selected
for detailed analysis. One hundred and forty three peptides were tested in donors that showed
positive responses for the corresponding pool. The scale ranges from yellow for strong
responses (up to 273 SFU/106 cells) to black for no response. Overall, 107 peptides (75% of the
peptides tested) induced IFN-γ production in at least one of the donors (S3 Table). As observed
for the peptide pools, the magnitudes of the responses to the individual peptides were low,
ranging from no response to ~0.03% of PBMC in individual donors. Most of the peptides that
induced positive responses (70%) were from proteins U57, U48 and U11 (27, 25 and 21 pep-
tides respectively). Fourteen peptides (Fig 3D, plus sign, and Table 4) showed positive IFN-γ
responses by either DFR2x or ER in at least 3 of the five donors. These were selected for valida-
tion and additional characterization. The protein U57 was found to be a predominant source
of peptides (6 out of 14) showing responses. Epitope information regarding to the peptides
studied here will be available in the Immune Epitope Database (http://www.iedb.org/).
Table 3. Summary of DRB1*01:01 binding predictions and IFN-γ responses.
Protein Name ORF Len1 All
predicted2
Selected3 Coverage4 Pools5 In 1+
donor6
In 4+
donors7
Peptides8 In 1+
donor9
In 3+
donors10
Glycoprotein Q U100 503 608 28 41 3 2 0 - - -
Major antigenic
phosphoprotein pp100
U11 647 850 36 44 4 4 3 27 21 2
Phosphoprotein pp85 U14 395 602 22 50 3 3 2 15 11 1
Glycoprotein B U39 830 822 48 45 5 5 1 10 5 1
Glycoprotein H U48 809 686 45 63 5 5 4 35 25 1
Virion transactivator U54 413 451 23 65 3 3 2 15 13 2
Major capsid protein U57 1345 1337 62 44 6 6 3 32 27 6
Large tegument protein U31 2077 2069 103 52 10 6 1 9 5 1
Major DNA binding
protein
U41 1132 1124 64 58 8 5 0 - - -
Immediate early protein1 U90 1078 1070 32 34 6 3 0 - - -
TOTAL 9619 463 43 53 42 16 143 107 14
1. Protein length (aa)
2. All 9-mers used for predictions
3. Number of selected 9-mers (top 5% of predicted 9-mers); these were synthesized as peptides after extension at the N and C-terminus
4. Protein coverage (%) considering all synthesized peptides
5. Total number of pools per protein. All these pools were tested for T cell responses
6. Number of positive pools in at least one donor
7. Number of positive pools in at least 4 donors
8. Total number of peptides in positive pools (4+ donors); these peptides were tested for T cell responses
9. Number of positive peptides in at least one donor
10. Number of positive peptides in at least 3 donors
doi:10.1371/journal.pone.0142871.t003
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Fig 3. Mapping of the CD4 T cell responses in PBMCs to HHV-6B proteins. A. IFN-γ ELISpot responses (SFU/106 cells) by donors #037, 118 and 132 to
pools 1–29. Error bars represent the standard deviation of the replicates. B. Heat maps summarizing the response of all donors (n = 5) to all pools tested (53).
Positive responses were assessed by DFR2x and ER analyses (see Methods). Pools for which positive responses were observed by DFR2x in at least 4
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Validation of selected CD4 T cell candidate epitopes
One potential complication of peptide-based epitope screening strategies is that cryptic
responses possibly might be observed, i.e. reactivity to epitope sequences that are not generated
during natural cellular processing of antigens [41]. To evaluate whether any of the fourteen
broadly recognized HHV-6B peptides described above represented cryptic epitopes, we evalu-
ated the reactivity of peptide-specific T cell cultures with epitopes generated by natural process-
ing in PBMCs pulsed with HHV-6B antigens. In-vitro expanded cells for each of the fourteen
peptides were generated from PBMCs of three different donors. These cells were tested for
IFN-γ production in response to autologous APCs pulsed with the exogenous peptide (P) or
the virus pellet (V) (Fig 4A). In all cases, the expanded cells that responded to APCs pulsed
with the exogenous peptide also responded to APCs pulsed with the virus. These results indi-
cate that epitopes contained in these peptides can be generated from the proteins expressed by
the virus via cellular antigen processing mechanisms, and thus represent bona fide viral
epitopes.
HHV-6B is related to HCMV, another member of the human beta-herpesvirus family, and
it is possible that the T cell specificities that we identified here might cross-react with similar
epitopes from HCMV. We tested for this cross-reactivity using the HHV-6B peptide-expanded
T cell cultures derived from two HCMV seronegative donors (#118 and #132, Table 1) in an
IFN-γ ELISpot assay (Fig 4B). Each culture was tested in parallel with an HCMV antigen prep-
aration and the HHV-6B virus pellet as described previously. No significant reactivity with
HCMV was observed for peptide-expanded cultures from the seronegative donors. For an
HCMV seropositive donor (#131, Table 1), weak reactivity with the HCMV viral preparation
donors were selected for further analysis and are indicated by (+). C. IFN-γ ELISpot responses by different donors to individual peptides in pools 5, 11, 23
and 29. D. Heat-maps summarizing the IFN-γ responses to individual peptides present in the pools selected in B. Positive responses to individual peptides
were assessed by ER and DFR2x analyses. Fourteen peptides that induced responses in multiple donors were selected for further validation, and are
indicated by (+).
doi:10.1371/journal.pone.0142871.g003
Table 4. Selected peptides exhibiting IFN-γ response in multiple donors.
Peptide Id Peptide sequence Protein Pool Response1 DRB1* Binding2
6BZ_1056 SINKLVYLGKLFVTLNQ U11 5 26 (4/4) 4600 (225)
6BZ_1073 DVDELKTLYNTFILWLM U11 5 32 (3/3) 810 (174)
6BZ_1025 LKETILDLAALISNMNL U14 8 32 (3/3) 2387 (161)
6BZ_107s LFLAVFLMNSVLMIYSD U39 11 67 (3/3) 4210 (870)
6BZ_1057 TRTHYLLLAKNGSVFEM U48 17 33 (4/3) 74 (13)
6BZ_1086s ELRYFKSGLGISPPSSS U54 21 19 (3/3) 3858 (482)
6BZ_1193 IVLNIFALPYANVTVSN U54 23 19 (4/3) 5006 (1537)
6BZ_1038 MGSKIQNLFSAFPIHAF U57 28 85 (4/3) 324 (39)
6BZ_1049s HYSNYAIGETIPLQLII U57 28 21 (4/3) 11 (1)
6BZ_1058 LQLTFFFPLGIYIPTET U57 28 17 (4/3) 36521 (2817)
6BZ_1063 MQTLLRKSPPQFIVLTM U57 28 20 (4/3) 7876 (480)
6BZ_1072 NLVSLIRLVKRTISISN U57 29 26 (3/3) 2276 (95)
6BZ_1084 PIGSIQKLTNILSQYIS U57 29 21 (5/ 4) 137(5)
6BZ_113 KLFIYIITQAWTASEDS U31 30 20 (4/3) 37(1)
1. Average IFN-γ response measured in fresh PBMCs; mean value (SFU/106 cells) with the number of donors testing positive over the number of donors
tested shown in parenthesis
2. DRB1*01:01 binding reported as IC50 in nM, with standard deviation shown in parenthesis
doi:10.1371/journal.pone.0142871.t004
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Fig 4. Validation of the IFN-γ response to selected HHV-6B peptides. Peptide-expanded T cell cultures to each of the 14 peptides in Table 4 were
generated for 3 donors, and tested for IFN-γ using ELISpot (SFU/106 cells). A. Responses of all expanded T cells to autologous PBMCs pulsed with the
peptide (P) or HHV-6B (V). ELISpot negative controls are indicated by (-). Positive responses were assessed by DFR2x and are indicated by (+) on top of the
bar. B. Summary of the responses of expanded T cells to autologous PBMCs pulsed with HCMV or HHV-6B for two HCMV seronegative (#118 and 132) and
one seropositive (#131) donor (Table 1). P-values for HCMV vs HHV-6B (unpaired t-test) are shown. C. Alignment of homologous HHV-6B U57 and HCMV
UL86 sequences in the region of known epitopes (boxes indicate the complete stimulating sequence). D. Response of a 6BZ_1084 CD4 T cell clone to
autologous BLCLs or PBMCs pulsed with HHV-6B 6BZ_1084 or with HCMV UL86-B peptides, as measured by IFN-γ ELISA. P-values for no-peptide vs
peptide (unpaired t-test) are shown.
doi:10.1371/journal.pone.0142871.g004
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was observed for each peptide-expanded culture (Fig 4B), probably representing HCMV-spe-
cific T cells originally present in peripheral blood and persisting in the expanded cultures.
For one of the fourteen HHV-6B epitopes recognized by multiple donors (6BZ_1084), the
corresponding sequence in HCMV contains a reported CD4 T cell epitope (Fig 4C) [42].
Although the HHV-6B and HCMV sequences have only 3 identities in the epitope region, at
several positions chemically similar residues are present. To test for potential cross-reactivity
between the corresponding epitopes from the two viruses, we isolated a T cell clone specific for
the 6BZ_1084 epitope from one of the seronegative donors, and tested this for cross-reactivity
with the corresponding HCMV epitope, using APCs pulsed with the HHV-6B peptide
(6BZ_1084) or the HCMV peptide (UL86-B). No reactivity with the HCMV peptide was
observed (Fig 4D), indicating that these epitopes do not cross-react.
Allele specificity and evaluation of binding prediction algorithms
The peptide-binding prediction algorithm that we used to identify potential HHV-6B epitopes
is based on one particular HLA-DR allele, DRB101:01. HLA-DR molecules in general have
broadly overlapping peptide binding specificities, with HLA-DRB101:01 the best character-
ized of a large group of alleles comprising the main HLA-DR supertype [43]. In previous work
we have found predictions based on this allele to be useful in identifying epitopes in donors
with a wide variety of HLA-DRB1 haplotypes [25,36]. That was the case in this study as well,
with donors of varying haplotypes responding well to the peptides tested, and with the sole
HLA-DRB101:01 donor not exhibiting stronger or more numerous response than the other
donors.
To evaluate the accuracy of the peptide binding predictions, we tested HLA-DRB101:01
binding for the 14 peptides exhibiting response in multiple donors, using a fluorescence-polari-
zation competition assay [39] (Table 4, S1 Fig). Each of the peptides bound with measurable
affinity, with IC50 values ranging from 11 nM to 37 μM. Peptides exhibiting responses in fewer
donors had IC50 values in the same range, whereas peptides for which T cell response were not
observed had significantly lower binding affinity (Fig 5A). In addition to the number of donors
responding, the abundance of specific T cells observed in PBMCs from responding donors also
correlated with the measured HLA-DRB101:01 binding affinity (Fig 5B).
To predict MHC-peptide binding affinity for the other HLA-DR1 alleles present in the
donor population, we used NetMHCIIPan 3.0 [37], a pan-specific MHC II neural network-
based prediction method (S4 Table). As expected, predicted peptide affinities for the various
HLA-DRB1 alleles investigated were highly correlated with that for HLA-DRB101:01, with
Pearson correlation coefficients varying from 0.48 to 0.81 (Fig 5C). Of the 463 peptides that we
had selected using the consensus-based approach to bind to HLA-DRB101:01, 442 were pre-
dicted by NetMHCIIPan 3.0 to bind to that same protein with IC50< 500 nM. For the other
alleles, the number of peptides predicted to have IC50< 500 nM ranged from 166 for
DRB104:07 to 484 for DRB107:01. Most of the donors were heterozygous at the DRB1 locus,
such that each donor had at least 321 peptides predicted to bind to one of their HLA-DR types
with IC50< 500 nM. NetMHCIIPan 3.0 also provides allele-specific predicted percentile rank
values, as the average IC50 value is predicted to differ for different HLA-DR proteins. For our
donors, the number of peptides predicted to be within the top 10% of all binders varied from
172 to 228 of the total 463 peptides tested, with 23 to 48 predicted to be within the top 1% of all
binders (S4 Table). Thus, the set of peptides that we selected using a DR1-based consensus
algorithm likely contains many peptides able to bind to other HLA-DR proteins present in our
donor population.
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We evaluated the ability of NetMHCIIPan 3.0 to predict immunogenicity within this set of
peptides on a donor-by-donor basis, using a receiver-operator characteristic (ROC) curve anal-
ysis (Fig 5D). The ROC evaluates the tradeoff between the true positive and false positive pre-
dictions as the criterion (here predicted IC50) is varied. As expected from previous studies of
allele-specific epitope prediction for MHC II proteins [44,45] and considering the limited
information on allele-specificity in our study, the predictive capacity was relatively low, with
Fig 5. HLA-DRB1*01:01 peptide binding affinity, predicted binding affinity for other HLA-DR alleles, and relation to observed T cell responses. A.
Measured HLA-DRB1*01:01 binding affinities grouped according to the frequency of positive responses, for peptides positive in 3 or more donors (n = 14),
peptides positive in 1–2 donors (n = 4) or peptides with no positive responses (n = 7). B. Correlation between measured HLA-DRB1*01:01 binding affinity
(IC50) and magnitude of T cell response (IFN-γ SFU/10
6 cells); Pearson’s correlation coefficient: -0.42 (p = 0.038). C. Correlation between predicted binding
affinities for HLA-DR alleles from donors examined in this study and predicted binding affinity for HLA-DRB1*01:01. D. Receiver-operator characteristic
(ROC) analysis relating predicted peptide-binding affinities for all peptides tested in each donor with CD4 T cell responses observed in that donor. Top left,
ROC analysis for fourteen peptides exhibiting strong responses in multiple donors.
doi:10.1371/journal.pone.0142871.g005
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areas under the ROC curve (AUC) ranging from 0.56 to 0.66, with only the latter value achiev-
ing statistical significance (for donor 118 DRB104:04/14:01) (S4 Table). These values can be
compared to AUC values of 0.5 for random predictions and 0.8 [44,45] for predictions of well-
characterized HLA-DR1-restricted epitopes. For the set of 14 selected epitopes for which we
observed responses in multiple donors, and considering responses in all of the donors, the
AUC value was 0.57 (p = 0.03). Despite the relatively low predictive value of the NetMHCIIPan
3.0 algorithm for predicting immunogenicity in this study, the algorithm predicted binding
affinity quite well. For these peptides for which we had experimental DRB101:01 binding
data, we compared NetMHCIIPan 3.0 predictions for HLA-DR1 with experimental IC50 val-
ues. Experimental binding values correlated with predicted IC50, with Pearson’s correlation
coefficient r = 0.89 and p<0.001 (S2 Fig).
Discussion
The experimental approach described in this report provides a systematic and cost-effective
method to identify immunodominant antigens and uncover T cell epitopes in large-genome
pathogens such as HHV-6B. We fractionated an HHV-6B virus preparation using denaturing
SDS-PAGE, identified fractions containing T cell antigens by direct analysis of excised gel
bands using in vitro cytokine secretion assays, and used mass spectrometry of tryptic digests to
characterize viral proteins present in those gel slices showing T cell reactivity. We used a con-
sensus-based epitope prediction algorithm to minimize the number of peptides from the iden-
tified viral proteins that needed to be tested, by selecting only candidate epitopes with the best
binding probabilities. These peptides were tested in pools and then individually in IFN-γ ELI-
Spot assays. Overall, 107 peptides from ten proteins induced in vitro T responses. Of these,
fourteen peptides exhibited strong responses in multiple donors across multiple HLA haplo-
types. These fourteen epitopes are generated by natural processing in infected cells, were not
cross-reactive with homologs from HCMV, and thus provide a basis for tracking HHV-6B-spe-
cific CD4 T cell responses in population and clinical studies.
Gel electrophoresis has been used previously to fractionate antigens for study of T cell
responses. A handful of studies in the late 80’s, early 90’s [46–52] and one in 2000 [53] reported
cellular responses to individual components in complex preparations of antigens fractionated
by SDS-PAGE. These reports were a logical extension of earlier studies using SDS-PAGE-frac-
tionated antigens as immunogens [54–56]. For these in vitro assays, antigens were separated by
SDS-PAGE, followed by transfer to nitrocellulose membranes, with release of proteins upon
treatment with DMSO [49]. However, inefficient transfer of low and high molecular weight
proteins could result in the loss of potential targets [57]. In addition, DMSO used to dissolve
membranes could interfere with subsequent cellular assays. Improved methods were developed
later, in which samples were fractionated using 2D gel electrophoresis, followed by electroelu-
tion of proteins and dialysis; this fractionation method avoided transfer of proteins to mem-
branes and eliminated the SDS in the sample, rendering protein fractions in a suitable solvent
for cellular assays [52,53,58]. Bhaskar et al [53] identified eight antigenic fractions of defined
molecular weight but did not report identification of the eluted M. tuberculosis antigens. In
our protocol, we used a one-dimension fractionation step, sidestepped transfer to nitrocellulose
membranes, and identified targets using proteomic workflows involving in-gel tryptic digestion
and LC-MS/MS analysis of tryptic peptides. It is possible that improved fractionation methods
might allow the identification of additional targets, potentially including low abundance HHV-
6B proteins, as in the recent identification of a human tumor antigen [59].
Our method of epitope identification has some advantages relative to other approaches.
Screening gel slices for immunogenicity facilitates selection of the major sources of antigens
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from the mixture, and reduces the number of proteins to be assayed relative to whole-genome
or whole-proteome approaches [25,60–62]. In this case, the number of potential candidate pro-
teins was reduced from ~100 HHV6-B proteins (or 36 proteins present in the extracellular
virus preparations, unpublished data) to 4 candidates (considering only screening done with
PBMCs to characterize high-frequency responses), or 8 candidates (considering screening
done with in vitro-expanded cells to include lower-frequency responses). Relative to
approaches in which the full set of virus-encoded gene products are screened using either
recombinant proteins [60,61,63] or overlapping peptide series [17,62], our method focuses epi-
tope identification work on the subset of proteins that induce strong responses. Relative to
approaches in which intact viral preparations are used as a source of antigen, the SDS-PAGE
step included in our approach is likely to eliminate viral immune evasion strategies by denatur-
ing all viral proteins. Viral proteins that down-modulate antigen presentation [64–66] and T
responses [67–69] are known to limit in vitro T cell responses to many viruses and HHV-6 in
particular [64]. In addition, upon electrophoresis, proteins are concentrated in gel regions that
upon excision provide enough material to trigger T cell responses. It is also possible that anti-
gens trapped in homogenized gel are more efficiently taken by professional antigen presenting
cells than soluble antigens, as shown by experiments with encapsulated antigens [70,71], or
that denaturation of viral proteins might facilitate antigen uptake and processing. In most
experiments we used extracellular virus preparations as a source of antigens, but we also
screened lysates of virus-infected cells in order to account for responses to viral proteins prefer-
entially present inside the infected cell. Two additional proteins (U41 and U90) were identified
in this manner, but the responses to peptides pools derived from these proteins were relatively
weak and further analysis was not performed.
There are also some caveats to our approach. The primary screening method relies on cellu-
lar processing of eluted proteins by APCs present in peripheral blood. The relative efficiency of
processing by this route might differ for eluted proteins relative to native proteins present in
viral particles or in infected cells, and so the observed immunodominance patterns might not
reflect those in vivo. Because of the requirement for cellular uptake of exogenous antigen,
responses would be expected to be biased towards CD4 rather than CD8 T cells, although
cross-presentation by PBMCs might contribute to observation of CD8 responses. In practice,
we observed predominantly CD4 responses. The SDS-PAGE step introduces some limitations:
small proteins (<10 kDa) might be lost during electrophoresis, and very large proteins might
not elute efficiently. However, we note that we did identify epitopes from several large proteins,
including the large tegument protein U31 with>2000 residues. It is possible that limited in-gel
proteolytic digestion before elution would improve detection of such large proteins. Finally, the
primary screening experiment is constrained by the resolution of SDS-PAGE and the amount
of sample available for screening excised gel bands. Reducing the size of the fractions increases
the chances that only one viral protein would be present per fraction, but this increases the
number of fractions that need to be tested in a single assay, and the availability of cells for the
IFN-γ assays is a limiting factor. We used 7.5% SDS-PAGE gels, in order to maximize separa-
tion in the 60–150 kDa region, where pilot experiments suggested the majority of the responses
where focused, and sliced the gels into ten fractions. Nonetheless, most fractions contained
multiple proteins. However, for each of the proteins identified in gel fractions with the excep-
tion of U100, multiple epitopes were recognized by our donor population. U100 peptide pools
were recognized mainly by one donor and so were not selected for detailed analysis, but strong
responses to some individual peptides from U100 were observed in PBMCs from that donor
(data not shown).
We used predicted binding to HLA-DR1 (DRB101:01) as a criterion to reduce the number
of peptides that would need to be tested in the second step of our epitope identification
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strategy. HLA-DR proteins share a common alpha subunit that contains many of the peptide
binding determinants [72], and as result peptide binding specificity is relatively promiscuous,
with overlapping peptide binding motifs for different HLA-DR alleles. Among the various
alleles for which peptide binding specificity has been characterized in detail, HLA-DR1 can be
considered as a “supertype” as its binding motif overlaps with many other alleles [43]. Previous
studies have provided experimental support for HLA-DR promiscuity in defined CD4 T cell
epitopes [36,73–75]. In the present study, the use of HLA-DR1 binding to sort candidate epi-
topes seems to be justified, based on retrospective analysis of immunogenicity in all donors of
various HLA haplotypes. The experimentally determined HLA-DR1 binding affinities were sig-
nificantly higher for epitopes recognized by multiple donors as compared to those not recog-
nized by any of the donors tested, and for epitopes associated with stronger responses as
measured by IFN-γ as compared to those associated with weaker responses. Moreover, positive
responses to selected peptides were observed for each donor tested, regardless of HLA-DR
haplotype.
We also retrospectively evaluated the utility of peptide binding predictions available for
other HLA-DR alleles in predicting CD4 T cells epitopes from immunogenic HHV-6B pro-
teins. For each of the HLA-DR alleles identified for each donor we used NetMHCIIPan 3.0
[37] to predict binding affinity for the set of 463 peptides tested in this analysis and compared
these predictions with the observed T cell responses. For the fourteen strong responses
observed in multiple donors, the predicted binding affinity was weakly but significantly associ-
ated with presence of T cell responses. However, for most of the individual donors, the predic-
tions were only slightly (and non-significantly) better than random guesses. Even for the
HLA-DRB101:01-positive donor 131, the predicted IC50 values were a poor guide to immuno-
genicity, despite the high correlation between predicted and observed binding affinity for this
allele. Inclusion of HLA-DQ and HLA-DP predictions potentially could increase the sensitivity
of this approach. It seems likely that epitope features in addition to MHC II binding affinity
play important roles in determining CD4 T cell immunogenicity [76]. Previously, we have
reported that resistance to HLA-DM editing is an important factor contributing to antiviral
CD4 immunogenicity [77], and it is possible that inclusion of HLA-DM effects could increase
the specificity of this epitope prediction approach.
It is noteworthy the diversity of the responses observed. Among 463 peptides tested, 107
provoked an IFN-γ response by circulating CD4 T cells from at least one donor. The profile of
the responses was different in the different donors tested. Some proteins have one epitope that
appears to dominate the response, for example peptide 6BZ_107 from U39, or peptide
6BZ_113 from U31, while for other proteins such as U48 there is not a clear dominant epitope,
and the response observed in pools of peptides seems to be the combination of responses to
many peptides. Some HHV-6B proteins induced responses in only specific donors, for example
U100 in donor 118, whereas other proteins were able to induce responses in most or all of the
donors (U57, U48, U11). The diversity of the response to HHV-6B may have an impact in ther-
apeutic applications. The finding that some of the epitope-specific responses were shared
among various donors led us to define a subset of 14 peptides that showed robust responses in
the majority of the donors. These could be useful for studying responses to HHV-6B in a het-
erogeneous population.
The set of epitopes reported here expands on previous studies of the HHV-6B immune
response. Of the 107 HHV-6B epitopes reported here, four (6BZ_020, 6BZ_1017, 6BZ_1051,
and 6BZ_1066) have been previously observed in studies of the human CD4 T cell responses to
HHV-6 (Nastke et al., 2012). Responses to these peptides were not observed in a majority of
donors tested here, and so they were not included in the set of 14 commonly recognized pep-
tides. However, the source proteins from which these 14 epitopes were derived overlap with
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proteins previously identified as sources of CD4 and CD8 epitopes. Five of the seven source
proteins (U11, U14, U48, U54, and U57) were previously observed by Naskte et al in studies of
the CD4 response [25]. U57 was a prominent source of CD4 epitopes in that study, as in the
work described here. Three of these proteins (U11, U14, and U54) also were identified as
sources of CD8 antigens [27,28,30].
In summary, we adapted a proteomics-based method for identifying prominent targets of
the cellular immune response to the ubiquitous pathogen HHV-6B. The method is based on
fractionation and characterization of virus preparations with limited screening of synthetic
peptides, and so can be used for pathogens such as HHV-6B, for which recombinant proteins
are not available and the large size of genome precludes systematic investigation of all potential
epitopes. Using this method we identified over one hundred individual HHV-6B-derived pep-
tides recognized by circulating CD4 T cells in healthy seropositive adults, the vast majority of
which represent previously unknown epitopes. Fourteen peptides from seven abundant virion
proteins were recognized by robust IFN-γ responses in a majority of donors tested. These rep-
resent a set of epitopes that should find application in tracking and potentially modifying cellu-
lar immunity to HHV-6B in basic research and clinical studies.
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